Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 474,300 shares, a decrease of 14.6% from the November 30th total of 555,600 shares. Currently, 23.7% of the company’s shares are sold short. Based on an average daily trading volume, of 660,100 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Aegis reissued a “buy” rating and issued a $15.00 price target on shares of Sunshine Biopharma in a report on Thursday, December 5th.

Sunshine Biopharma Stock Down 0.3 %

Shares of NASDAQ:SBFM traded down $0.01 during midday trading on Friday, reaching $3.06. The company’s stock had a trading volume of 56,616 shares, compared to its average volume of 265,924. Sunshine Biopharma has a 12-month low of $2.11 and a 12-month high of $599.80. The firm has a market capitalization of $3.75 million, a P/E ratio of -0.02 and a beta of 1.42. The firm has a 50 day moving average of $2.81 and a 200-day moving average of $2.14.

Sunshine Biopharma (NASDAQ:SBFM) last announced its earnings results on Tuesday, November 5th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of $9.00 by ($9.94). Sunshine Biopharma had a negative net margin of 12.82% and a negative return on equity of 17.89%. The business had revenue of $8.44 million for the quarter.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.